{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif
PARP-BC-PPC Survey
  1. In your clinical practice, what is the average number of breast cancer patients do you see per month? *
  2. In your clinical practice, what % of breast cancer patients are currently undergoing germline BRCA mutation testing *
    3. %
  3. In your clinical practice, what % of HER2-ve early breast cancer patients are likely to have germline BRCA mutations? *
    4. Indication % gBRCAm
    HER2 Negative and HR positive EBC
    %
    Triple negative EBC
    %
  4. In your clinical practice, what % of HER2-ve metastatic breast cancer patients are likely to have germline BRCA mutations? *
    5. Indication % gBRCAm
    HER2 Negative and HR positive mBC
    %
    Triple negative mBC
    %
  5. As per your clinical practice, what is the average duration for which patient continues on Olaparib: *
    6. gBRCAm HER2-ve early breast cancer
    Months
    gBRCAm HER2-ve locally advanced or metastatic
    Months
    Not sure
    Months
  6. In your clinical practice, what % of Olaparib treated breast cancer patient requires dose reductions? *
    7. %
  7. If patient is non-affordable for Olaparib, do you use Rucaparib in gBRCAm HER2-ve breast cancer patients?

  8. In your clinical practice, approximately what % of prostate cancer patients undergo BRCA/HRR testing? *
    9. %
  9. At what stage do you recommend BRCA/HRR genetic testing for your prostate cancer patients? *

  10. In your clinical practice, which of the following genetic test do you recommend to metastatic prostate cancer patients? *

  11. In your clinical practice, what % of mCRPC patients have BRCA mutation? *
    12. %
  12. In real world scenario, what is the average PFS with Rucaparib in BRCAm mCRPC patient progressed on NHA (newer hormonal agents) & Docetaxel *
    13. months
  13. In your clinical practice, what % of metastatic pancreatic cancer patients have gBRCA mutation? *
    14. %
  14. As per your clinical experience, what % of metastatic pancreatic cancer patients have ECOG PS of 0-1? *
    15. %
  15. Considering advantages of Olaparib in management of gBRCAm metastatic pancreatic cancer, what % of your patients would actually receive Olaparib in clinical practice ? *